Deep Venous Thrombosis and Pulmonary Embolism: Current Therapy

Area of Science:

• Cardiovascular Medicine
• Hematology
• Pharmacology

Background:

• Venous thromboembolism (VTE), encompassing pulmonary embolism and deep venous thrombosis, is a major cardiovascular disease.
• Anticoagulation is the cornerstone of VTE management.
• Outpatient treatment is feasible for many deep venous thrombosis and low-risk pulmonary embolism cases.

Purpose of the Study:

• To outline current treatment strategies for venous thromboembolism (VTE).
• To discuss the role of various anticoagulants and treatment settings.
• To provide guidance on VTE management duration and special circumstances.

Main Methods:

• Review of current anticoagulation therapies for VTE.
• Comparison of outpatient versus inpatient VTE treatment approaches.
• Discussion of specific anticoagulant agents, including heparin, warfarin, and direct-acting oral anticoagulants.
• Consideration of adjunctive therapies like thrombolysis and vena cava filters.
• Guideline recommendations for treatment duration and special populations.

Main Results:

• Low-molecular-weight heparin and vitamin K antagonists or direct-acting oral anticoagulants are common for outpatient VTE treatment.
• Parenteral agents, preferably low-molecular-weight heparin, initiate inpatient VTE care.
• Unfractionated heparin is reserved for specific clinical scenarios like hemodynamic instability or renal insufficiency.
• Direct-acting oral anticoagulants offer an alternative but have cost and reversing agent considerations.
• Concomitant heparin administration is required for initiating warfarin, dabigatran, or edoxaban.
• Thrombolytic therapy may benefit hemodynamically unstable patients with low bleeding risk.
• Inferior vena cava filters are not indicated for patients on anticoagulation.
• A minimum of three months of anticoagulation is recommended, with longer durations individualized.
• Special populations like pregnant or cancer patients may require long-term heparin therapy.
• Asymptomatic distal deep venous thrombosis may be monitored, with treatment initiated upon extension.

Conclusions:

• Anticoagulation remains the primary treatment for VTE, with tailored approaches for different patient groups and settings.
• The choice of anticoagulant and treatment duration depends on clinical factors, patient risk, and specific VTE manifestations.
• Individualized risk-benefit analysis is crucial for decisions regarding extended anticoagulation therapy beyond the initial three months.